Palatin Technologies, Inc. (PTN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, CEO & Director | 979k | -- | 1962 |
| Mr. Stephen T. Wills CPA, MST | CFO, COO, Executive VP, Treasurer & Secretary | 910.55k | -- | 1957 |
| Burns McClellan | Vice President of Investor Relations | -- | -- | -- |
| Mr. Stephen A. Slusher Esq. | Chief Legal Officer | -- | -- | -- |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer | -- | -- | -- |
| Mr. James E. Hattersley | Senior Vice President of Business Development | -- | -- | 1960 |
| Mr. John Dodd Ph.D. | Senior Vice President of Preclinical Development | -- | -- | -- |
| Mr. Robert Jordan | Senior Vice President of Program Operations | -- | -- | -- |
Palatin Technologies, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 34
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Corporate Governance
Upcoming Events
May 15, 2024 at 11:30 AM UTC
Palatin Technologies, Inc. Earnings Date